Regulus: First subject dosed in second cohort of Phase 1b MAD study of RGSL8429

Regulus Therapeutics announced the dosing of the first patient in the second cohort of the Phase 1b MAD study of RGSL8429 for the treatment of ADPKD. “Following the positive safety review of patients in the first cohort, we were excited to initiate screening for the second cohort last month,” said Jay Hagan, CEO of Regulus Therapeutics. “Now with dosing of the first patient in the second cohort, our Phase 1b MAD trial is progressing well. We are on track to deliver topline data from the first cohort around the end of the third quarter of this year. This is another important milestone in our effort to develop a novel treatment for patients with ADPKD.”